Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
57 words
A reagent which is adapted to be labelled with technetium-99m for use as a hepato-biliary imaging radiopharmaceutical for use on an animal, the reagent comprising a stannous complex of a phenolic aminocarboxylic acid chelating agent selected from the group consisting of an ethylene diamine di(hydroxy phenyl carboxylic acid) and a di (hydroxy benzyl) ethylene diamine dicarboxylic acid.
Claim 2
Dependent Claim
57 words
A reagent which is adapted to be labelled with technetium-99m for use as a hepato-biliary imaging radiopharmaceutical for use on an animal, the reagent comprising a stannous complex of a phenolic aminocarboxylic acid chelating agent selected from the group consisting of an ethylene diamine di(hydroxy phenyl carboxylic acid) and a di (hydroxy benzyl) ethylene diamine dicarboxylic acid.
Claim 3
Dependent Claim
41 words
A reagent as claimed in claim 1, wherein said chelating agent is selected from the group consisting of ##STR5## wherein X is hydrogen, a halogen or an alkyl group and ##STR6## wherein X is hydrogen, a halogen or an alkyl group.
Claim 4
Dependent Claim
49 words
A reagent which is adapted to be labelled with technetium-99m for use as a hepato-biliary imaging radiopharmaceutical for use on an animal, the reagent comprising a stannous complex of a phenolic aminocarboxylic acid chelating agent containing a single phenolic group, having a balance of both lipo-soluble and water-soluble properties.
Claim 5
Dependent Claim
49 words
A reagent which is adapted to be labelled with technetium-99m for use as a hepato-biliary imaging radiopharmaceutical for use on an animal, the reagent comprising a stannous complex of a phenolic aminocarboxylic acid chelating agent containing a single phenolic group, having a balance of both lipo-soluble and water-soluble properties.
Claim 6
Dependent Claim
23 words
A reagent as claimed in claim 3, wherein said chelating agent is selected from the group consisting of hydroxybenzyl glycine and hydroxybenzyl sarcosine.
Claim 7
Dependent Claim
19 words
A reagent as claimed in claim 4, wherein said phenolic aminocarboxylic acid has lipo-solubilizing substituents in the phenolic ring.
Claim 8
Dependent Claim
14 words
A reagent as claimed in claim 5, wherein said lipo-solubilising substituent is a halogen.
Claim 9
Dependent Claim
18 words
A reagent as claimed in claim 2, wherein the reagent is a stannous chelate of ethylene-bis-(α-imino-2-hydroxy-5-bromophenyl acetic acid).
Claim 10
Dependent Claim
19 words
A reagent as claimed in claim 2, wherein the reagent is a stannous chelate of N,N'-bis-(2-hydroxy-5-bromobenzyl ethylenediamine diacetic acid).
Claim 11
Dependent Claim
52 words
A reagent which is adapted to be labelled with technetium-99m for use as a hepato-biliary imaging radiopharmaceutical on an animal, the reagent being a stannous chelate of a chelating agent selected from the group consisting of hydroxybenzyl glycine and hydroxybenzyl sarcosine having lipo-solubilizing substituents in the phenolic ring and having aliphatic substituents.
Claim 12
Dependent Claim
52 words
A reagent which is adapted to be labelled with technetium-99m for use as a hepato-biliary imaging radiopharmaceutical on an animal, the reagent being a stannous chelate of a chelating agent selected from the group consisting of hydroxybenzyl glycine and hydroxybenzyl sarcosine having lipo-solubilizing substituents in the phenolic ring and having aliphatic substituents.
Claim 13
Dependent Claim
16 words
A reagent as claimed in claim 9, wherein said lipo-solubilising substituents are selected from the halogens.
Claim 14
Dependent Claim
16 words
A reagent as claimed in claim 4, wherein the reagent is a stannous chelate of N-(o-hydroxybenzyl)glycine.
Claim 15
Dependent Claim
16 words
A reagent as claimed in claim 4, wherein the reagent is a stannous chelate of N-(o-hydroxybenzyl)sarcosine.
Claim 16
Independent Claim
78 words
A method of forming radiopharmaceuticals for assessing hepato-biliary function in animals, comprising reacting a stannous chelate of a chelating agent selected from the group consisting of lipo-solubilizing ring substituted derivatives of ##STR7## wherein X is hydrogen, a halogen or an alkyl group, ##STR8## wherein X is hydrogen, a halogen or an alkyl group, (3) hydroxybenzyl glycine and (4) hydroxybenzyl sarcosine with a radio isotope selected from the group consisting of 111 In or 113m In and 99m Tc.
Claim 17
Independent Claim
78 words
A method of forming radiopharmaceuticals for assessing hepato-biliary function in animals, comprising reacting a stannous chelate of a chelating agent selected from the group consisting of lipo-solubilizing ring substituted derivatives of ##STR7## wherein X is hydrogen, a halogen or an alkyl group, ##STR8## wherein X is hydrogen, a halogen or an alkyl group, (3) hydroxybenzyl glycine and (4) hydroxybenzyl sarcosine with a radio isotope selected from the group consisting of 111 In or 113m In and 99m Tc.
Claim 18
Dependent Claim
34 words
A radiopharmaceutical for assessing hepato-biliary function comprising a lipo-soluble metal chelate in which the metal is a pharmaceutically acceptable radio isotope for an animal and the metal chelate is formed from ethylene-bis(α-imino-2-hydroxy-5-bromophenyl acetic acid).
Claim 19
Dependent Claim
34 words
A radiopharmaceutical for assessing hepato-biliary function comprising a lipo-soluble metal chelate in which the metal is a pharmaceutically acceptable radio isotope for an animal and the metal chelate is formed from ethylene-bis(α-imino-2-hydroxy-5-bromophenyl acetic acid).
Claim 20
Dependent Claim
67 words
A radiopharmaceutical for assessing hepato-biliary function comprising a lipo-soluble metal chelate in which the metal is a pharmaceutically acceptable radio isotope for an animal and the metal chelate is formed from a stannous complex of a chelating agent selected from the group consisting of ##STR9## wherein X is hydrogen, a halogen or an alkyl group and ##STR10## wherein X is hydrogen, a halogen or an alkyl group.
Claim 21
Dependent Claim
67 words
A radiopharmaceutical for assessing hepato-biliary function comprising a lipo-soluble metal chelate in which the metal is a pharmaceutically acceptable radio isotope for an animal and the metal chelate is formed from a stannous complex of a chelating agent selected from the group consisting of ##STR9## wherein X is hydrogen, a halogen or an alkyl group and ##STR10## wherein X is hydrogen, a halogen or an alkyl group.